Evidence map›Paper›PMID 33579720›Full record

ArticleEuropean journal of hospital pharmacy : science and practice2022

Outcomes of

Bojana Milenković, Vesna Šuljagić, Aneta Perić, Viktorija Dragojević-Simić, Olivera Tarabar, Milomir Milanović, Vesna Putić, Diana Tomić, Branislava Miljković, Sandra Vezmar Kovačević

Open access · greenAbstract read
In one paragraph

Article in European journal of hospital pharmacy : science and practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Clinical Characteristics and Risk Factors ofJournal of clinical medicine · 2026
    Article
  2. Management ofEClinicalMedicine · 2025
    Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Colon cancer andProceedings (Baylor University. Medical Center) · 2024
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Bojana MilenkovićDepartment of Pharmacy, Military Medical Academy, Belgrade, Serbia boxy87@gmail.com.ORCID 0000-0003-4830-6917
Vesna ŠuljagićMedical Faculty University of Defence, Belgrade, Serbia.
Aneta PerićDepartment of Pharmacy, Military Medical Academy, Belgrade, Serbia.
Viktorija Dragojević-SimićMedical Faculty University of Defence, Belgrade, Serbia.
Olivera TarabarMedical Faculty University of Defence, Belgrade, Serbia.
Milomir MilanovićMedical Faculty University of Defence, Belgrade, Serbia.
Vesna PutićDepartment of Pharmacy, Military Medical Academy, Belgrade, Serbia.
Diana TomićInstitute of Microbiology, Military Medical Academy, Belgrade, Serbia.
Branislava MiljkovićDepartment of Pharmacokinetics and Clinical Pharmacy, Faculty of Pharmacy University of Belgrade, Belgrade, Serbia.
Sandra Vezmar KovačevićDepartment of Pharmacokinetics and Clinical Pharmacy, Faculty of Pharmacy University of Belgrade, Belgrade, Serbia.
Military Medical Academy · RSUniversity of Belgrade · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

methodsA prospective cohort study was conducted including adult patients diagnosed with an initial episode of HA CDI. Their demographic and clinical characteristics associated with risk factors for CDI were documented. Outcomes such as all-cause 30-day mortality, cure of infection, diarrhoea relaps and recurrence of disease were followed. Patients were assigned to cancer and non-cancer groups. Within the cancer group, patients were divided into the solid tumour subgroup and haematological malignancy subgroup.

resultsDuring a 7-year period, HA CDI was observed in 28 (5.1%) patients with haematological malignancy, 101 (18.3%) patients with solid tumours and 424 (76.7%) non-cancer patients. Older age (OR 1.04, 95% CI 1.02 to 1.07, p<0.001), admission to the intensive care unit (ICU) (OR 2.61, 95% CI 1.37 to 4.95, p=0.003), mechanical ventilation (OR 5.19, 95% CI 2.78 to 9.71, p<0.001) and use of antibiotics prior to CDI (OR 1.04, 95% CI 1.02 to 1.06, p=0.02) were associated with increased mortality. Compared with patients with solid tumours, patients with haematological malignancy were younger (65 vs 57 years, p=0.015), did not require ICU admission (25.0% vs 0%) or mechanical ventilation (8.9% vs 0%) and were treated longer with antibiotics prior to CDI (14 vs 24 days, p=0.002).

conclusionsPatients with haematological malignancy were exposed to different risk factors for CDI associated with mortality compared with patients with solid tumours and non-cancer patients. Older age, ICU stay and mechanical ventilation, but not presence or type of cancer, predicted the all-cause 30-day mortality.

Indexed as

Clostridioides difficileClostridium InfectionsNeoplasmsAdultHumansProspective StudiesTertiary Care Centersclinical medicinecontrolled clinical trialdrug-related side effects and adverse reactionseducation departmentgastrointestinal neoplasmshead and neck neoplasmshematologyhospitalkidney neoplasmsleukemiamicrobiologymultiple myelomatransplantationurologic neoplasms

Identifiers

PMID33579720
PMCPMC8899674
OpenAlexW3127040626

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.